Recent Developments in Australian & US Patent Law & their Impact ...

More documents

Recommendations

Info

Personalized Medicine Intellectual Property Protection Ausbiotech 2012 – Australian and US Patent Law 1 November 2012 6 ACLU et al. v. USPTO and Myriad Genetics (Fed. Circ., 2012) Mayo Collaborative Services et al. v. Prometheus Laboratories Inc. (Supreme Court, 2012)
Personalized Medicine – Gene/Biomarker Patents Ausbiotech 2012 – Australian and US Patent Law 1 November 2012 7 5,882,914 (HIF-1α - Expires 2016) • An isolated polynucleotide encoding the human hypoxia-inducible factor-1 alpha polypeptide of SEQ ID NO:2. 5,593,884 (JNK - Expires 2014) • An isolated polynucleotide sequence encoding a polypeptide characterized by: a. having a molecular weight of 46 kD as determined by reducing SDS-PAGE; b. having serine and threonine kinase activity; and c. phosphorylating the c-Jun N-terminal activation domain. 5,827,733 (GDF-8/myostatin - Expires 2013) • An isolated polynucleotide selected from the group consisting of: a) SEQ ID NO:11; b) SEQ ID NO:13; c) SEQ ID NO:11, wherein T can also be U; d) SEQ ID NO:13, wherein T can also be U; e) nucleic sequences complementary to SEQ ID NO:11… 6,132,728 Hedgehog (Expires 2017) 5,777,079 Green Fluorescent Protein (GFP) (Expires 2015)
Page 1 and 2: Ausbiotech 2012 RECENT DEVELOPMENTS
Page 3 and 4: Ausbiotech 2012 - Australian and US
Page 5: Patent eligibility Ausbiotech 2012
Page 9 and 10: Personalized Medicine - Myriad Gene
Page 11 and 12: Personalized Medicine - Prometheus
Page 13 and 14: Australia - Patent Eligible Subject
Page 21 and 22: USA - Infringement Exemptions
Page 23 and 24: Bolar Exemption (Roche v. Bolar (Fe
Page 27 and 28: Momenta Pharmaceuticals v. Amphasta
Page 29 and 30: Regulatory approval - pharmaceutica
Page 33: Ausbiotech 2012 RECENT DEVELOPMENTS

Recent Developments in Australian & US Patent Law & their Impact ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?